Celgene's Revlimid combo causes stir at ASH
The results of a Phase III trial of a combination using Celgene Corp's Revlimid will change clinical practice for patients with multiple myeloma, experts have said. - News - PharmaTimes
by Liliane Anekwe
www.pharmatimes.com/news/celgenes_revlimid_combo_causes_stir_at_ash_1006186